ORLANDO — The Board of Directors of the Association for Accessible Medicines (AAM) has named as its new Chairperson, Christine Baeder, Teva Pharmaceuticals USA Chief Operating Officer for U.S. Generics and Biosimilars.
Baeder succeeds Chirag Patel, Amneal Pharmaceuticals Inc.’s Co-Founder, President, and Co-Chief Executive Officer, as AAM Board of Directors Chairman.
“The generics and biosimilars industry is an exemplar of the value that can be delivered to Americans by manufacturers, policymakers, and regulators working together. However, the industry is at a crossroads and faces real threats to its survival. No other sector helps patients afford their health care as much as generic, complex generic and biosimilar medicines, which are needed not only to create access but to free up resources to enable new and novel therapies,” said Baeder. “I am humbled that my peers have chosen me to lead at this critical time and determined to be the most forceful and effective advocate possible.”
“We are delighted to welcome Christine with her steady commitment to the industry and demonstrated leadership in her new role as AAM Board Chair,” said David Gaugh, Interim CEO of AAM. “Christine is exactly the right person to lead the membership at this time. She has the strength and focus to advance our industry’s mission to providing safe, effective, and more affordable medicines to American patients.”
AAM also named Keren Haruvi, President of Sandoz U.S. and Head of North America as Vice Chair of the Board, and Jeff Burd, President, Ajanta Pharma USA Inc. as Treasurer.
Comments are closed.